




Trading Update 1st Quarter 2008

Q1 figures determined by temporary decline of turnover in Belgium and Spain

Nazareth (Belgium), 17 April 2008 (5:45 PM CET) – The consolidated turnover in the first quarter of 2008 totalled 196.0 miljoen euro. The evolution of the turnover per business unit is as follows:

Non-audited management figures in EUR million	First quarter		
	2008	2007	evolution
Belgium	46.5	54.2	-14%
France	46.9	45.6	+3%
Northern Europe	23.6	23.5	+1%
Southern Europe	42.2	44.8	-6%
Rest Of World	36.8	36.6	+1%
Omega Pharma (OTC)	196.0	204.8	-4%

Contribution to the consolidated turnover of the first quarter of 2008



Overview by business unit

- **Belgium** experienced a 14% decrease in turnover which mainly relates to generic medicines. Trend analysis indicates that growth can be expected again as of the third quarter of 2008.

- The organization in **France** has succeeded in achieving a growth of turnover, despite difficult market conditions in the first quarter of 2008. The XLS slimming products generated 12% more turnover than in the same period last year.
- The local organizations in Scandinavia continued the solid performance of recent quarters. Wartner (wart removal), ACO and Cosmica (skin care) perform particularly well. Within the **Northern Europe** region this achievement is largely offset by the performance in Germany. The uptake of the turnover of Claire Fisher (skin care) in this country is encouraging for the future.
- In **Southern Europe** turnover is down 6% from same period last year, due to an incidental difficult quarter in Spain after two years of double digit growth. New innovative product launches are expected in the second quarter. The Italian organization achieved a remarkable success with the upgrade of the Angstrom sun protection product.
- Turnover in **Rest of World** remained flat. Growth is expected in the second quarter of 2008 now that the new management structure in Central and Eastern Europe is fully operational. Turnover in the UK, in GBP, grew slightly. The outsourcing of sales activities, which are henceforward conducted in partnership with Ceuta Healthcare, has been fully implemented. The Dutch organization introduced innovative versions of Davitamon (e.g. Davitamon Vitz chewing gum) as well as the Dermalex Repair assortment (products for treating eczema and skin irritations).

Focus on brands

On group level, the following ten brands (listed alphabetically) yielded the highest contribution to the turnover in the first quarter: ACO (skin care, Scandinavia), Angstrom (sun products, Italy), Clément Thékan (health products for pets, France), Davitamon (vitamins, Western Europe), Paranix (anti-head lice, Western Europe), Phytosun Arômes (aroma therapy, France/Belgium), Predictor (home diagnostics, Western Europe), Silence (anti-snoring product, Western Europe), Wartner (wart removal, Western Europe), and XLS (slimming, Western Europe). In total, they represent 33% of the consolidated turnover in the first quarter 2008. Worth mentioning is Silence, with a quarterly turnover of over 5 million euro, which is included in this selective list at this early stage as a result of its rapid introduction in numerous countries where Omega Pharma operates.

Share buy-back

On 31 March 2008 Omega Pharma owned 2,234,994 treasury shares. The current mandate for purchasing own shares is valid until 5 May 2008, at which time the proposal to cancel 2 million treasury shares will be submitted to the Extraordinary Shareholders Meeting.

Prognosis ⁽¹⁾

Omega Pharma confirms its previous prognosis of achieving an internal growth of between 3% and 7% in 2008. This is based on strengthened management structures, synergies, and scheduled product launches, including **Paradust**, a revolutionary product against allergies caused by dust mites scheduled for launch in various European countries in the course of 2008.

Group turnover is expected to evolve positively again as of the second quarter 2008.

Omega Pharma, a pure OTC play

Since its creation in 1987, Omega Pharma has grown into a multinational group with almost 1,900 staff and with operations in 30 countries spread over Western, Central, and Eastern Europe. Omega Pharma is one of the few companies dealing solely in OTC products. With its current geographical spread, the group is poised to enter the worldwide Top Ten ranking in the market for over-the-counter medicines and personal care products.

(1) Disclaimer: This press release contains forward-looking information which is based on current internal estimates and expectations as well as market expectations. Forward-looking statements contain inherent risks and apply exclusively on the date they are made. The actual results may differ substantially from those included in the forward-looking statements.

For more information, please contact: Marc Coucke, CEO - tel. 0032/9/381 02 15

Shareholder calendar

Monday 5 May 2008 (7:00 PM CET)	General shareholders meeting, Nazareth (Belgium)
Thursday 17 July 2008 (5:45 PM CET)	Trading Update (turnover) 2 nd quarter and 1 st half 2008
Thursday 28 August 2008 (5:45 PM CET)	Half Year 2008 Results
Friday 12 September 2008	Investors Day
Thursday 16 October 2008 (5:45 PM CET)	Trading Update (turnover) 3 rd quarter 2008
Thursday 22 January 2009 (5:45 PM CET)	Trading Update (turnover) 4 th quarter 2008 and FY 2008